Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage biotechnology firm headquartered in San Diego, California, dedicated to pioneering innovative immunotherapies for cancer treatment. The company leverages its proprietary platform of genetically modified oncolytic viruses to selectively target malignant cells and enhance the body’s immune response, establishing itself as a key player in the immuno-oncology landscape. With a strong pipeline driven by promising clinical trials, Calidi Biotherapeutics is committed to addressing substantial unmet medical needs in oncology, with the goal of transforming cancer care standards and optimizing patient outcomes.

NYSE MKT

USA

HEALTHCARE

BIOTECHNOLOGY

4475 EXECUTIVE DRIVE, SAN DIEGO, CA, UNITED STATES, 92121

December

$8.31 Million

-$19.3 Million

3.222

0.36

$0.00

0.0%

1.092